Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Weiland

Showing results (71-80 of 167) with videos related to

Pageof 17
Sort By:
The Journal of General Virology|October 21, 1998
The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responsesC Hultgren, D R Milich, O Weiland, et al.
Progress in Clinical and Biological Research|January 1, 1991
Successful treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection explained by inhibitory effect on the immune response?B G Hansson, K Riesbeck, E Nordenfelt, et al.
Infection|November 1, 1990
Acute hepatitis B and hepatitis D co-infection in the Stockholm region in the 1970s and 1980s--a comparisonG Lindh, L Mattsson, M von Sydow, et al.
Journal of Medical Virology|May 1, 1995
Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon aloneR Schvarcz, Z B Yun, A Sönnerborg, et al.
Scandinavian Journal of Infectious Diseases|January 1, 1994
Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccineJ Struve, B Aronsson, B Frenning, et al.
Journal of Hepatology|January 1, 1990
Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experienceO Weiland, R Schvarcz, R Wejstål, et al.
Lakartidningen|August 22, 1990
[All blood donors should be tested to stop the transmission of hepatitis C virus]C Högman, S Iwarson, A Lindholm, et al.
Infection|September 1, 1994
Treatment of chronic replicative hepatitis B virus infection with short-term continuous infusion of foscarnetR Schvarcz, B G Hansson, J O Lernestedt, et al.
Journal of Medical Virology|August 13, 1998
Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatmentJ Odeberg, Z Yun, A Sönnerborg, et al.
The Journal of Infection|November 1, 1995
Risk factors for hepatitis A, B and C virus infection among Swedish expatriatesJ Struve, O Norrbohm, J Stenbeck, et al.
Pageof 17

Showing results (71-80 of 167) with videos related to

Sort By:
Pageof 17
The Journal of General Virology|October 21, 1998
The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responsesC Hultgren, D R Milich, O Weiland, et al.
Progress in Clinical and Biological Research|January 1, 1991
Successful treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection explained by inhibitory effect on the immune response?B G Hansson, K Riesbeck, E Nordenfelt, et al.
Infection|November 1, 1990
Acute hepatitis B and hepatitis D co-infection in the Stockholm region in the 1970s and 1980s--a comparisonG Lindh, L Mattsson, M von Sydow, et al.
Journal of Medical Virology|May 1, 1995
Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon aloneR Schvarcz, Z B Yun, A Sönnerborg, et al.
Scandinavian Journal of Infectious Diseases|January 1, 1994
Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccineJ Struve, B Aronsson, B Frenning, et al.
Journal of Hepatology|January 1, 1990
Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experienceO Weiland, R Schvarcz, R Wejstål, et al.
Lakartidningen|August 22, 1990
[All blood donors should be tested to stop the transmission of hepatitis C virus]C Högman, S Iwarson, A Lindholm, et al.
Infection|September 1, 1994
Treatment of chronic replicative hepatitis B virus infection with short-term continuous infusion of foscarnetR Schvarcz, B G Hansson, J O Lernestedt, et al.
Journal of Medical Virology|August 13, 1998
Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatmentJ Odeberg, Z Yun, A Sönnerborg, et al.
The Journal of Infection|November 1, 1995
Risk factors for hepatitis A, B and C virus infection among Swedish expatriatesJ Struve, O Norrbohm, J Stenbeck, et al.
Pageof 17